Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells

Hepatology

Volumn 62, Issue 6, 2015, Pages 1710-1722

  Wang, Yanan ^a   van der Tuin, Sam ^a   Tjeerdema, Nathanja ^a   van Dam, Andrea D ^a   Rensen, Sander S ^b   Hendrikx, Tim ^c   Berbée, Jimmy F P ^a   Atanasovska, Biljana ^d   Fu, Jingyuan ^d   Hoekstra, Menno ^e   Bekkering, Siroon ^f   Riksen, Niels P ^f   Buurman, Wim A ^b   Greve, Jan Willem ^b   Hofker, Marten H ^d   Shiri Sverdlov, Ronit ^c   Meijer, Onno C ^a   Smit, Johannes W A ^a,f   Havekes, Louis M ^a   van Dijk, Ko Willems ^a   Rensen, Patrick C N ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN;

ADULT; AGED; ANIMAL; FEMALE; HUMAN; KUPFFER CELL; MALE; METABOLISM; MIDDLE AGED; MOUSE; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; KUPFFER CELLS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED;

EID: 84955180472     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27985     Document Type: Article

References (45)

1. McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B. Kupffer cell function in host defense. Rev Infect Dis 1987;9(Suppl 5):S616-S619.
2. Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc 2004;37:16-28.
3. Takeishi T, Hirano K, Kobayashi T, Hasegawa G, Hatakeyama K, Natio M. The role of Kupffer cells in liver regeneration. Arch Histol Cytol 1999;62:413-422.
4. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-1186.
5. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511-531.
6. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006;54:229-239.
7. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
8. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
9. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012;302:G1310-G1321.
10. Bieghs V, Walenbergh SM, Hendrikx T, van Gorp PJ, Verheyen F, Olde Damink SW, et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int 2013;33:1056-1061.
11. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 2012;287:40161-40172.
12. De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012;30:49-56.
13. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007;22:491-497.
14. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-858.
15. Le GW, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004;101:17-38.
16. Karalis I, Rensen PC, Jukema JW. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ Cardiovasc Qual Outcomes 2013;6:360-366.
17. Drayna D, Jarnagin AS, McLean J, Henzel W, Kohr W, Fielding C, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987;327:632-634.
18. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-1274.
19. van Eck M, Ye D, Hildebrand RB, Kruijt JK, De Haan W, Hoekstra M, et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 2007;100:678-685.
20. Pape ME, Rehberg EF, Marotti KR, Melchior GW. Molecular cloning, sequence, and expression of cynomolgus monkey cholesteryl ester transfer protein. Inverse correlation between hepatic cholesteryl ester transfer protein mRNA levels and plasma high density lipoprotein levels. Arterioscler Thromb 1991;11:1759-1771.
21. Li Z, Wang Y, Van der Sluis RJ, Van der Hoorn JW, Princen HM, Van Eck M, et al. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. Biochem Pharmacol 2012;84:821-829.
22. Wolfs MG, Rensen SS, Bruin-Van Dijk EJ, Verdam FJ, Greve JW, Sanjabi B, et al. Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study. BMC Med Genomics 2010;3:34.
23. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992;90:1290-1295.
24. Geier A, Zollner G, Dietrich CG, Wagner M, Fichert P, Denk H, et al. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology 2005;41:470-477.
25. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012;109:17537-17542.
26. Radeau T, Robb M, Lau P, Borthwick J, McPherson R. Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis 1998;139:369-376.
27. De Grooth GJ, Smilde TJ, Van Wissen S, Klerkx AH, Zwinderman AH, Fruchart JC, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004;173:261-267.
28. Movita D, Kreefft K, Biesta P, Van Oudenaren A, Leenen PJ, Janssen HL, et al. Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages. J Leukoc Biol 2012;92:723-733.
29. Greenawalt DM, Dobrin R, Chudin E, Hatoum IJ, Suver C, Beaulaurier J, et al. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res 2011;21:1008-1016.
30. Westerterp M, Van der Hoogt CC, De Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2552-2559.
31. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-197.
32. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153(Suppl 1):S68-S75.
33. Van der Hoogt CC, De Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijm JA, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007;48:1763-1771.
34. Van der Hoorn JW, De Haan W, Berbee JF, Havekes LM, Jukema JW, Rensen PC, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-2022.
35. Asztalos BF, Swarbrick MM, Schaefer EJ, Dallal GE, Horvath KV, Ai M, et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res 2010;51:2405-2412.
36. Johansson LE, Danielsson AP, Parikh H, Klintenberg M, Norstrom F, Groop L, et al. Differential gene expression in adipose tissue from obese human subjects during weight loss and weight maintenance. Am J Clin Nutr 2012;96:196-207.
37. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-137.
38. Wang Y, Snel M, Jonker JT, Hammer S, Lamb HJ, De Roos A, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL. Diabetes Care 2011;34:2576-2580.
39. Wolfs MG, Gruben N, Rensen SS, Verdam FJ, Greve JW, Driessen A, et al. Determining the association between adipokine expression in mutliple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes 2015;5:e146.
40. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000;105:513-520.
41. Gautier T, De Haan W, Grober J, Ye D, Bahr MJ, Claudel T, et al. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res 2013;54:2195-2205.
42. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
43. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009;29:268-275.
44. Masucci-Magoulas L, Moulin P, Jiang XC, Richardson H, Walsh A, Breslow JL, Tall A. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest 1995;95:1587-1594.
45. Lakomy D, Rebe C, Sberna AL, Masson D, Gautier T, Chevriaux A, et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler Thromb Vasc Biol 2009;29:1923-1929.